PRINCIPIA BIOPHARMA INC.

Profile

Company Names

PRINCIPIA BIOPHARMA INC.

Addresses

400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO, CA 94080

C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK, CA 94025

Phone Numbers

(650) 416-7700
(650) 234-2700

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, OTHER HEALTH CARE

Year Incorporated:

2008

State Incorporated:

DELAWARE

Total Amount Raised:

$77,401,795.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2018-08-16 
$49,999,978.00 
$49,999,978.00 
$0.00 
Equity 
2
2015-07-21 
$15,285,151.00 
$15,292,200.00 
$7,049.00 
Equity 
1
2011-02-10 
$12,116,666.00 
$36,349,998.00 
$24,233,332.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SRINIVAS 
 
AKKARAJU 
DIRECTOR
SEATTLE GENETICS INC /WA   |  PRESIDIO PHARMACEUTICALS, INC.   |  VERSARTIS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  SYROS PHARMACEUTICALS, INC.   |  SAMSARA BIOCAPITAL, L.P.   |  565 SPV I, L.P.   |  TENTARIX BIOTHERAPEUTICS, LP   |  CHINOOK THERAPEUTICS U.S., INC.   |  MINERALYS THERAPEUTICS, INC.   |  ORSOBIO, INC.   |  VTV THERAPEUTICS INC.   |  ALUMIS INC.   |  SAMSARA OPPORTUNITY FUND, L.P.
SRINI 
 
AKKARAJU, M.D., PH.D. 
DIRECTOR
PRINCIPIA BIOPHARMA INC.
MARTIN 
 
BABLER 
EXECUTIVE OFFICER, DIRECTOR
INFINITY PHARMACEUTICALS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  ALUMIS INC.
DANIEL 
 
BECKER 
DIRECTOR
WATCHWITH, INC.   |  NEURANA PHARMACEUTICALS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  DTX PHARMA, INC.   |  DAY ONE BIOPHARMACEUTICALS HOLDING CO LLC   |  MATCHPOINT THERAPEUTICS INC.   |  ARETEIA THERAPEUTICS, INC.
ELIOT 
 
CHARLES 
EXECUTIVE OFFICER
PRINCIPIA BIOPHARMA INC.
ALAN 
 
COLOWICK 
DIRECTOR
NORA THERAPEUTICS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  VELOSBIO INC.   |  INCARDA THERAPEUTICS, INC.   |  SOLVE THERAPEUTICS, INC.   |  RECODE THERAPEUTICS, INC.   |  ANUMANA, INC.   |  HARPOON THERAPEUTICS, INC.   |  ALUMIS INC.
MICHAEL 
 
DYBBS 
DIRECTOR
VERSARTIS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  SAMSARA BIOCAPITAL, L.P.   |  SUTRO BIOPHARMA INC   |  NKARTA, INC.   |  565 SPV I, L.P.   |  LEVO THERAPEUTICS, INC.   |  DELFI DIAGNOSTICS, INC.   |  ABCURO, INC.   |  SAMSARA OPPORTUNITY FUND, L.P.
SIMEON 
 
GEORGE 
DIRECTOR
SEMPRUS BIOSCIENCES CORP   |  GENOCEA BIOSCIENCES, INC.   |  HTG MOLECULAR DIAGNOSTICS INC   |  AUXOGYN INC   |  EFFECTOR THERAPEUTICS, INC.   |  HTG MOLECULAR DIAGNOSTICS, INC   |  AUXOGYN, INC.   |  PRINCIPIA BIOPHARMA INC.   |  PROGYNY, INC.   |  TP THERAPEUTICS, INC.   |  CRISPR THERAPEUTICS AG   |  SR ONE CO-INVEST I, LLC   |  SIMCHA THERAPEUTICS HOLDING COMPANY, LLC   |  ADARX PHARMACEUTICALS, INC.   |  SR ONE CAPITAL FUND II-B, LP   |  SR ONE CAPITAL FUND II-A, LP   |  AVENZO THERAPEUTICS, INC.   |  REZO THERAPEUTICS, INC.   |  SR ONE CAPITAL FUND III, LP
SIMEON 
J. 
GEORGE, M.D. 
DIRECTOR
PRINCIPIA BIOPHARMA INC.   |  EFFECTOR THERAPEUTICS, INC.
RICHARD 
A. 
MILLER, M.D. 
DIRECTOR
PRINCIPIA BIOPHARMA INC.
LEWIS 
J. 
SHUSTER 
DIRECTOR
QUIKBYTE SOFTWARE INC   |  RESPONSE BIOMEDICAL CORP   |  PRINCIPIA BIOPHARMA INC.   |  TP THERAPEUTICS, INC.
LEWIS J. 
 
SHUSTER 
DIRECTOR
PRINCIPIA BIOPHARMA INC.
PETER 
 
THOMPSON 
DIRECTOR
TRUBION PHARMACEUTICALS, INC   |  RESPONSE BIOMEDICAL CORP   |  TV ONE LLC   |  TV ONE CAPITAL CORP.   |  CODA THERAPEUTICS INC   |  METHYLGENE INC.   |  CARDIOXYL PHARMACEUTICALS INC   |  PRONAI THERAPEUTICS INC   |  EQDERIVATIVES, INC.   |  ADAPTIMMUNE LTD   |  CORVUS PHARMACEUTICALS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  E-SCAPE BIO, INC.   |  ALPINE IMMUNE SCIENCES, INC.   |  CLEAVE BIOSCIENCES, INC.   |  PMV PHARMACEUTICALS, INC.   |  PREVAIL THERAPEUTICS INC.   |  SYNTHORX, INC.   |  ALPINE IMMUNE SCIENCES, INC.   |  EDGEWISE THERAPEUTICS, INC.   |  SILVERBACK THERAPEUTICS, INC.   |  RECODE THERAPEUTICS, INC.   |  ESCAPE BIO, INC.   |  CRANIOVATION, INC.   |  SPARROW PHARMACEUTICALS, INC.   |  ALPHEUS MEDICAL, INC.   |  GENNAO BIO, INC.   |  TERREMOTO BIOSCIENCES, INC.
PETER 
 
THOMPSON, M.D. 
EXECUTIVE OFFICER, DIRECTOR
PRINCIPIA BIOPHARMA INC.   |  JANUX THERAPEUTICS, INC.
NASSIM 
 
USMAN 
DIRECTOR
OSPREY PHARMACEUTICALS USA INC   |  MOSAIC BIOSCIENCES, INC.   |  CATALYST BIOSCIENCES INC   |  PRINCIPIA BIOPHARMA INC.
NASSIM 
 
USMAN, M.D. 
DIRECTOR
PRINCIPIA BIOPHARMA INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2018-09-05
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2018-08-16 
2015-08-04
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2015-07-21 
2011-02-23
D
Link
OTHER HEALTH CARE 
 
DECLINE TO DISCLOSE 
Equity 
2011-02-10 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
N/A
NONE